Brief: Theravance Biopharma Announces Orphan Drug Designation Granted To Ampreloxetine
09/05/2023 23:18
May 9 (Reuters) - Theravance Biopharma Inc TBPH.O :
* THERAVANCE BIOPHARMA, INC. ANNOUNCES ORPHAN DRUG
DESIGNATION
GRANTED TO AMPRELOXETINE FOR THE TREATMENT OF SYMPTOMATIC
NEUROGENIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH MULTIPLE
SYSTEM ATROPHY
Source text for Eikon: ID:nPn5s9YCDa
Further company coverage: TBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Theravance Biopharma
See all newsTheravance Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Brief: Theravance Biopharma Q2 Operating Income USD -8.277 Million
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions